Reuteri 21st Anniversary: Reaching New Heights in Evidence-Based Probiotics

Recent medical research highlights that probiotics optimize gut microbiota, thereby strengthening immunity and reducing illness risks. As a probiotic trailblazer, Reuteri was introduced to Hong Kong in 2005. Adhering strictly to scientific data, its efficacy is highly endorsed by the medical community and consumers. This year, BioGaia (Reuteri) was recognized as the No. 1 Children’s Probiotic Supplement Brand in Europe and Latin America. Backed by over 302 clinical studies, recommended by 17 international medical guidelines, and adopted by multiple private hospitals in Hong Kong, it stands as the premier choice for professional gut health.

Celebrating two decades of partnership and uncompromising quality

To commemorate this milestone, J-Health recently hosted the 21st-anniversary academic symposium and dinner, themed "Redefining the Standard: Evidence-based Application of Reuteri in FGIDs" (Functional Gastrointestinal Disorders). The prestigious event gathered nearly a hundred local private hospital and clinic doctors, community pharmacists, and registered dietitians to explore the latest clinical breakthroughs of the L. reuteri DSM 17938 strain.

Clinical insights on functional abdominal pain and probiotic selection 

Shedding light on the scientific foundation behind the strain, Gianfranco Grompone, Chief Scientific Officer of BioGaia noted: "L. reuteri DSM 17938 is a probiotic strain from human origin. It was isolated from breast milk from a Peruvian mother in the late 80s." He added: “If you consider all BioGaia (Reuteri)  probiotics, we are talking about 300 randomized control trials, most of them double-blind, placebo-controlled trials. This is a huge amount of clinical evidence, which shows first of all the safety of this strain, but also the efficacy.”

"Functional abdominal pain is actually one of the most common causes of abdominal pain in children. It causes a long-standing effect not only to the child, but also to the family," pointed out Iva Hojsak, Secretary General of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition.

Addressing how to properly select a suitable probiotic, Iva Hojsak further explained: "The answer is quite easy and clear, because there are randomized control trials, six of them showing the efficacy of L. reuteri in reducing the intensity of pain in patients with functional abdominal pain. So, we always recommend this specific strain because the evidence is only on that side, and we need to take into consideration that it needs to be taken for at least 4 weeks to see real benefits."

Commitment to scientific excellence, quality, and long-term partnership

Amelie Coyet, Deputy Consul General, Consulate General of Sweden in Hong Kong, remarked: "J-Health and BioGaia’s partnership demonstrates the impact we can co-create when Swedish innovators work with trusted local partners that understand the culture and market here in Hong Kong."

Highlighting corporate excellence, Ulf Björkdahl, Chief Commercial Officer of BioGaia (Reuteri) , stated: "At BioGaia (Reuteri) ,science is the core of what we do. And we adhere to our core values, which are innovation, passion, and collaboration." He added regarding compliance and standards: "If you look at sustainability, we are among the top 15 of the EcoVadis sustainability rating. We are FSC certified and among the top ESG industry performers. And within quality, we are GMP certified as well as HACCP certified. And all our products have GRAS status by FDA in the US, as well as QPC by EFSA in the EU."

Ophelia Lin, Founder and Managing Director of J-Health, stated: "Back in 2005, when we first introduced Reuteri to Hong Kong, we did so with a singular and unwavering mission to deliver the gold standard in probiotics, backed by one of the most clinically studied and scientifically validated strains in the world. Reaching this remarkable 21 years milestone would not have been possible without your steadfast support. And in particular, our extraordinary partnership with BioGaia (Reuteri) .”

Human-derived efficacy and advanced proprietary protection

Reuteri fundamentally relies on empirical science, selecting the patented, human-breast-milk-derived strain L. reuteri DSM 17938. This natural strain effectively survives gastric acid and bile to colonize the human GI tract, maximizing its efficacy within the human body. Notably, it is the only probiotic brand in the market equipped with LongevityGuard™ technology, comprehensively ensuring probiotic viability. The brand offers tailored formulations spanning all life stages from infancy—addressing gut health, gastric health, immunity, and skin sensitivities—and remains widely trusted by private hospital doctors. Reuteri will continue to explore probiotic applications in gastrointestinal health, bringing more evidence-based choices to Hong Kong.

Reuteri Probiotics Chewable Tablets are suitable for individuals frequently troubled by gas, bloating, indigestion, bowel movement difficulties, or diarrhea. They also regulate immune cell functions, improve skin allergies, and alleviate vaginal discomfort in women, making them ideal for daily maintenance among children, the elderly, pregnant women, and those prone to malabsorption. 

For those with deeper gastric concerns, the brand introduces Reuteri Gastrus Probiotics Chewable Tablets, combining the patented strains DSM 17938 and ATCC PTA 6475. This formulation effectively improves excessive gastric acid secretion, relieves gas and bloating discomfort, alleviates stomach aches and functional abdominal pain, mitigates nausea and vomiting in pregnant women, inhibits stubborn Helicobacter bacteria, and enhances gastric immunity, rendering it exceptionally well-suited for individuals with chronic gastric discomfort,Helicobacter bacteria carriers, and expectant mothers. 

BioGaia Reuteri Ecz-immune + D3 Probiotics merge the DSM 17938 strain with Vitamin D3 to effectively soothe eczema and sensitive skin symptoms, upper respiratory sensitivity discomfort, and abdominal bloating caused by lactose intolerance, while further balancing the intestinal microflora and boosting resistance, making them particularly beneficial for individuals prone to eczema and sensitivities. 

Additionally, targeting newborns, infants, and toddlers or seniors with swallowing difficulties, Reuteri has specially designed a liquid oil drop series. Reuteri Probiotics Drops effectively reduce infant colic and gas, improve bowel difficulties and diarrhea, mitigate lactose intolerance symptoms, and soothe skin sensitivities. Meanwhile, Reuteri Probiotics D Drops preserve all the original gastrointestinal health and sensitivity-soothing benefits while providing an extra boost to promote healthy bone and tooth development.

Learn more: https://reuteri.com.hk/en/products-3/